Taral Patel

Taral Patel

UNVERIFIED PROFILE

Are you Taral Patel?   Register this Author

Register author
Taral Patel

Taral Patel

Publications by authors named "Taral Patel"

Are you Taral Patel?   Register this Author

27Publications

629Reads

17Profile Views

Efficacy and Safety Results of the Afatinib Expanded Access Program.

Oncol Ther 2017 10;5(1):103-110. Epub 2017 Apr 10.

Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40487-017-0043-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488108PMC
April 2017

Intensity modulated radiation therapy with simultaneous integrated boost based dose escalation on neoadjuvant chemoradiation therapy for locally advanced distal esophageal adenocarcinoma.

World J Gastrointest Oncol 2016 May;8(5):474-80

Ming Zeng, Fernando N Aguila, Taral Patel, Mark Knapp, Xue-Qiang Zhu, Xi-Lin Chen, Phillip D Price, Department of Radiation Oncology, Mount Carmel Health System, Columbus, OH 43219, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4251/wjgo.v8.i5.474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865715PMC
May 2016

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

J Thorac Oncol 2014 Sep;9(9):1411-7

*University of California Los Angeles, Los Angeles, CA; †Kaiser Permanente Northern CA, Antioch, CA; ‡Sarah Cannon Research Institute, Nashville, TN; §Northwest Medical Specialties, Tacoma, WA; ‖Sibley Memorial Hospital, Washington, DC; ¶Integrated Community Oncology Network, Jacksonville, FL; #The Mark H. Zangmeister Center, Columbus, OH; **Florida Cancer Specialists, Bonita Springs, FL; ††Arch Medical Services Inc., The Center for Cancer Care and Research, Saint Louis, MO; ‡‡National Taiwan University, Taipei, Taiwan; §§F. Hoffmann-La Roche Ltd., Basel, Switzerland; ‖‖Genentech Inc., South San Francisco, CA; ¶¶Weill Cornell Medical College and Thoracic Oncology Service, New York, NY; and ##Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000274DOI Listing
September 2014

Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy.

J Am Coll Cardiol 2014 May 18;63(18):1879-89. Epub 2014 Jan 18.

President's Office, Touro College, Brooklyn, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2013.12.021DOI Listing
May 2014

Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.

Anticancer Drugs 2013 Nov;24(10):1084-92

aVall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain bMedStar Washington Hospital Center, Washington Cancer Institute, Washington, District of Columbia cMid Ohio Oncology/Hematology Inc., The Mark H. Zangmeister Center, Columbus, Ohio dGenentech, South San Francisco, California eMemorial Sloan-Kettering Cancer Center, New York, New York, USA fRiga East University Hospital Oncology Center, Riga, Latvia gDaugavpils Reǵionālā Slimnīca, Daugavpils, Latvia hGesundheitszentrum Fricktal, Spital Rheinfelden & Laufenburg, Rheinfelden, Switzerland iNational Hospital Organization Osaka National Hospital, Osaka-City, Osaka, Japan jRoche Products Limited, Welwyn Garden City, UK kPharsight, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000016DOI Listing
November 2013

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

J Clin Oncol 2013 Nov 7;31(32):4105-14. Epub 2013 Oct 7.

David R. Spigel, Thomas J. Ervin, and Davey B. Daniel, Sarah Cannon Research Institute; David R. Spigel, Tennessee Oncology, Nashville; Davey B. Daniel, Chattanooga Oncology Hematology Associates, Chattanooga, TN; Thomas J. Ervin, Florida Cancer Specialists, Fort Myers; Michael S. Wertheim, Hematology/Oncology Associates, Port St Lucie, FL; Rodryg A. Ramlau, Poznan University of Medical Sciences, Poznan; Maciej J. Krzakowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Jerome H. Goldschmidt Jr, Blue Ridge Cancer Care, Christianburg, VA; George R. Blumenschein Jr, The University of Texas MD Anderson Cancer Center, Houston, TX; Gilles Robinet, University Hospital Morvan, Brest; Benoit Godbert, Centre Hospitalier Universitaire Nancy, Vandoeuvre-lès-Nancy; Fabrice Barlesi, Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, Marseille, France; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Taral Patel, Mid Ohio Oncology/Hematology, Columbus, OH; Sergey V. Orlov, St Petersburg Pavlov State Medical University, St Petersburg, Russia; Wei Yu, Robert L. Yauch, Premal H. Patel, and See-Chun Phan, Genentech; Amy C. Peterson, Medivation, San Francisco, CA; and Jiping Zha, Crown Bioscience, Taicang City, China.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/10/07/JCO.2012.47
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.47.4189
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.47.4189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878106PMC
November 2013

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

J Clin Oncol 2013 Nov 7;31(31):3926-34. Epub 2013 Oct 7.

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA; Fairooz Kabbinavar, University of California Los Angeles, Translational Oncology Research International, Los Angeles; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Chin-Yu Lin and Chris Bowden, Genentech, South San Francisco; Jonathan Polikoff, Southern California Permanente Medical Group, San Diego, CA; John Hainsworth, Sarah Cannon Research Institute, Nashville, TN; Saifuddin Kasubhai, Northwest Medical Specialties, Tacoma, WA; Bruce Kressel, Sibley Memorial Hospital, Washington, DC; Thomas Marsland, Integrated Community Oncology Network, Orange Park; Mark Rubin, Florida Cancer Specialists, Fort Myers, FL; Taral Patel, The Mark H. Zangmeister Center, Columbus, OH; Leonard White, Arch Medical Services, The Center for Cancer Care and Research, Saint Louis, MO; Vincent Miller, Weill Cornell Medical College and Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; and James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.3983DOI Listing
November 2013

Atrial fibrillation and stroke: the evolving role of rhythm control.

Curr Treat Options Cardiovasc Med 2013 Jun;15(3):299-312

Division of Cardiology, Department of Internal Medicine, Northwestern University, Feinberg School of Medicine, 251 East Huron Street, Feinberg 8-503, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11936-013-0234-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651784PMC
June 2013

Prevalence and predictors of cable extrusion and loss of electrical integrity with the Riata defibrillator lead.

J Cardiovasc Electrophysiol 2012 Nov 14;23(11):1207-12. Epub 2012 Jun 14.

Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1540-8167.2012.02378.xDOI Listing
November 2012

Left atrial appendage exclusion for stroke prevention in atrial fibrillation.

Cardiol Res Pract 2012 16;2012:610827. Epub 2012 Oct 16.

Division of Cardiology, Department of Internal Medicine, Feinberg School of Medicine, Northwestern University, 251 East Huron Street, Feinberg 8-503E, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/610827DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480004PMC
November 2012

Do symptoms matter when considering patients for phase I clinical trials?: a pilot study of older adults with advanced cancer.

Am J Hosp Palliat Care 2011 Nov 10;28(7):463-6. Epub 2011 Mar 10.

Department Medicine, Division of Geriatrics, Gerontology, and Palliative Care, University of Texas Health Science Center at San Antonio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1049909111400723DOI Listing
November 2011

A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis.

Eur Heart J 2007 Mar 22;28(6):664-72. Epub 2007 Jan 22.

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehl445DOI Listing
March 2007

Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.

Invest New Drugs 2006 Nov;24(6):537-42

Division of Cancer Treatment and Diagnosis, National Cancer Institute, City of Hope National Medical Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-006-9244-8
Publisher Site
http://dx.doi.org/10.1007/s10637-006-9244-8DOI Listing
November 2006

Using statins to treat inflammation in acute coronary syndromes: Are we there yet?

Cleve Clin J Med 2006 Aug;73(8):760-6

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3949/ccjm.73.8.760DOI Listing
August 2006

A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis.

Am J Cardiol 2006 Jun 21;97(12):1685-90. Epub 2006 Apr 21.

Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S000291490600419
Publisher Site
http://dx.doi.org/10.1016/j.amjcard.2006.01.028DOI Listing
June 2006

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

J Clin Oncol 2005 Jun 28;23(16):3697-705. Epub 2005 Feb 28.

Division of Hematology/Oncology, UCLA School of Medicine, 10945 LeConte Ave, Suite 2338J, Los Angeles, CA 90095-7187, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.05.112DOI Listing
June 2005

Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction.

Arch Intern Med 2004 Apr;164(8):852-6

Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archinte.164.8.852DOI Listing
April 2004